Intelligent Bio Solutions Inc. (INBS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Diagnostics & Research industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Harry Simeonidis.
INBS tiene fecha de IPO 2020-12-23, 50 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.8M.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
